

## United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/026,188		12/21/2001	Charles S. Zuker	02307E-114910US	9521
20350	7590	07/23/2004		EXAM	IINER
		TOWNSEND AND	BRANNOCK, MICHAEL T		
TWO EMBARCADERO CENTER EIGHTH FLOOR			ART UNIT	PAPER NUMBER	
		CA 94111-3834		1646	

DATE MAILED: 07/23/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	10/026,188	ZUKER ET AL.				
Office Action Summary	Examiner	Art Unit				
	Michael Brannock	1646				
The MAILING DATE of this communication ap Period for Reply	pears on the cover sheet with the c	correspondence address				
A SHORTENED STATUTORY PERIOD FOR REPL THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a rep If NO period for reply is specified above, the maximum statutory period.  - Failure to reply within the set or extended period for reply will, by statut Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	136(a). In no event, however, may a reply be timely within the statutory minimum of thirty (30) day will apply and will expire SIX (6) MONTHS from the cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on N/A						
2a) This action is <b>FINAL</b> . 2b) ⊠ Thi	s action is non-final.					
3) Since this application is in condition for allows closed in accordance with the practice under						
Disposition of Claims						
4) ☐ Claim(s) 1-15 is/are pending in the application 4a) Of the above claim(s) is/are withdra 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) 1-15 are subject to restriction and/or	awn from consideration.					
Application Papers						
9) The specification is objected to by the Examiner.						
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
,						
Priority under 35 U.S.C. § 119  12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:  1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority document application from the International Bureat * See the attached detailed Office action for a list	nts have been received. Its have been received in Applicationity documents have been received in Application (PCT Rule 17.2(a)).	on No ed in this National Stage				
Attachment(s)  1) Notice of References Cited (PTO-892)	4)  Interview Summary	(PTO-413)				
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Da	ate				
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08 Paper No(s)/Mail Date	5) Notice of Informal P 6) Other:	Patent Application (PTO-152)				

## **DETAILED ACTION**

## Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-9 and 12-15, as the claims relate to SEQ ID NO: 2, drawn to methods of modulating the activity of a rat L-TRP protein and for identifying modulators of said protein, classified in class 435, subclass 7.21.
- II. Claims 1-9 and 12-15, as the claims relate to SEQ ID NO: 5, drawn to methods of modulating the activity of a murine LTRP5 protein and for identifying modulators of said protein, classified in class 435, subclass 7.21.
- III. Claims 1-9 and 12-15, as the claims relate to SEQ ID NO: 8, drawn to methods of modulating the activity of a human LTRP5 protein and for identifying modulators of said protein, classified in class 435, subclass 7.21
- IV. Claims 10 and 11, as the claims relate to SEQ ID NO: 2, drawn to methods of identifying binding partners of a rat L-TRP protein, classified in class 436, subclass 501.
- V. Claims 10 and 11, as the claims relate to SEQ ID NO: 5, drawn to methods of identifying binding partners of a murine LTRP5 protein, classified in class 436, subclass 501.

Application/Control Number: 10/026,188

Art Unit: 1646

VI. Claims 10 and 11, as the claims relate to SEQ ID NO: 5, drawn to methods of identifying binding partners of a human LTRP5 protein, classified in class 436, subclass 501.

The inventions are distinct, each from the other because of the following reasons:

Although there are no provisions under the section for "Relationship of Inventions" in M.P.E.P. § 806.05 for inventive groups that are directed to different methods, restriction is deemed to be proper because these methods appear to constitute patentably distinct inventions for the following reasons: The methods of Groups I-III are distinct both physically and functionally from the methods of Groups IV-VI, and are not required one for the other. Groups I-III require an assay for activity which is not required by any of the other Groups IV-VI. Conversely, Groups IV-VI require an assay of binding, which is not required by any of the other Groups I-III. The methods of each of Groups I and IV require a rat protein, which is not required by any of the other groups. The methods of each of Groups III and V require a murine protein, which is not required by any of the other groups. The methods of each of Groups III and VI require a human protein, which is not required by any of the other groups.

Therefore, because these inventions are distinct for the reasons given above and because a search and examination of all the groups in one patent application would result in an undue burden, since the searches for the groups are not co-extensive, the classification is different, and the subject matter is divergent, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143). Applicant is reminded that upon the cancellation of claims to a non-elected invention,

Page 4

Application/Control Number: 10/026,188

Art Unit: 1646

the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

## Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael Brannock, Ph.D., whose telephone number is (571) 272-0869. The examiner can normally be reached on Mondays through Fridays from 10:00 a.m. to 4:00 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brenda Brumback, Ph.D., can be reached at (571) 272-0961.

Official papers filed by fax should be directed to (703) 872-9306. Faxed draft or informal communications with the examiner should be directed to (703) 308-0294.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

MB

July 19, 2004

ELIZABETH KEMMERER PRIMARY EXAMINER

Elyabeth C. Kemmeres